Pharmaceutical - Zonegran


Current filters:


Popular Filters

FDA clears Eisai Zonegran facility in UK for US exports

FDA clears Eisai Zonegran facility in UK for US exports


Eisai says the US Food and Drug Administration has approved the US supply of the epilepsy drug Zonegran…

EisaiEuropeNeurologicalNorth AmericaPharmaceuticalProductionRegulationZonegran

Eisai gains Swiss approval for Zonegran and Canadian OK for Fycompa


Japanese drug major Eisai (TYO: 4205) says that Zonegran (zonisamide) has been approved by Switzerland's…

EisaiEuropeFycompaNeurologicalNorth AmericaPharmaceuticalRegulationZonegran

Eisai joins trend to enter Russian pharma market, with Halaven launch


Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced…

EisaiEuropeExaliefFycompaHalavenInovelonMarkets & MarketingNeurologicalOncologyPharmaceuticalZonegran

News briefs: Priority review for ocriplasmin; Zonegran monotherapy in EU


Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR) says that the US Food and Drug Administration…

EisaiEuropeNeurologicalNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenicsZonegran

Zonegran Russian approval prompts Eisai's expansion in that market


Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia,…

EisaiEuropeFycompaHalavenMarkets & MarketingNeurologicalPharmaceuticalRegulationZonegran

Eisai updates on epilepsy drugs Zonegran, Zebinix and perampanel at IEC


Japanese drug major Eisai (TYO: 4523) presented new data at the International Epilepsy Congress taking…


Eisai epilepsy drug delayed by US FDA, but Zonegran use extension filing accepted in EU


There was disappointment for Japanese drug major Eisai (TYO: 4523) last week when the US Food and Drug…

EisaiEuropeNeurologicalNorth AmericaperampanelPharmaceuticalRegulationZonegran

Back to top